Targeting GPR39 to treat cognitive decline related to aging
Official title: GPR39 as a Therapeutic Target in Aging-Related Vascular Cognitive Impairment and Dementia
Funded at Oregon Health & Science University · NIH-10734713 · Data updated 2026-11-12
This study is looking at a brain receptor called GPR39 to see if a new small medicine can help improve thinking and memory in older adults with vascular cognitive impairment and dementia, aiming to find better treatments to enhance their quality of life.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2026 |
| Funding year | 2023 |
| Award (this year) | $2,244,471 |
| NIH project number | 1RF1AG079890-01A1 |
| Project ID | NIH-10734713 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are older adults experiencing cognitive decline, particularly those diagnosed with vascular cognitive impairment or dementia.
✕Less likely to help
Patients with cognitive impairment due to causes other than vascular issues, such as Alzheimer's disease or other neurodegenerative disorders, may not benefit from this research.
What this research studies
This research investigates the role of GPR39, a receptor in the brain, as a potential therapeutic target for vascular cognitive impairment and dementia (VCID), which is a common form of dementia in older adults. The study aims to develop a new small molecule that can effectively penetrate the central nervous system and activate GPR39, potentially improving cognitive function. Researchers will utilize advanced screening methods to identify effective compounds and assess their impact on cognitive health in aging populations. By understanding the underlying mechanisms of VCID, the research seeks to pave the way for innovative treatments that could enhance the quality of life for affected individuals.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve cognitive function and quality of life for patients suffering from vascular cognitive impairment and dementia.
How similar studies have gone: While targeting GPR39 is a novel approach, previous research has shown promise in similar pathways for treating cognitive decline, indicating potential for success.
Where this research is happening
-
Oregon Health & Science University
Portland, United States Active
Researchers
- Principal investigator: Alkayed, Nabil J — Oregon Health & Science University
- Study coordinator: Alkayed, Nabil J
Related research
Other NIH-funded projects on the same topics.
-
GPR39-based treatment approach for aging-related brain vascular dementia
A new drug-style compound that activates GPR39 in the brain is being studied to help people with vascular dementia linked to aging.
-
Global picture of dementia risk and memory loss across the world
A large international effort gathers data from many studies to understand how dementia and memory problems develop around the world, using shared information to reveal patterns and risk factors.
-
Long-term Effects of a Natural Disaster on Cognitive Aging and Dementia in Older Adults
This project follows older adults affected by a major natural disaster to understand how long-term stress may influence aging, memory, and risk for dementia.
-
Health, Aging and Dementia in South Africa: A Longitudinal Study
A long-term study in South Africa follows adults 40 and older to understand how aging affects dementia and Alzheimer’s, using surveys, cognitive tests, and biomarkers.
-
Health, Aging and Dementia in South Africa: A Longitudinal Study
A long-term study in South Africa follows adults as they age to understand how dementia and Alzheimer’s affect people in LMIC settings.
-
Health, Aging and Dementia in South Africa: A Longitudinal Study
A long-term study in South Africa follows adults as they age to better understand dementia and related factors.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.